Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07312734 · ClinicalTrials.gov registry record
Study to Enable New Diagnostics for Pulmonary Microbes in People With CF
A clinical trial, sponsored by Chris Goss.
- Recruiting
- Registry status
- 300
- Enrollment target
NCT07312734 is a clinical trial that is actively recruiting participants, run by Chris Goss. The registered enrollment target is 300 participants.
The verdict
NCT07312734 is actively recruiting participants, sponsored by Chris Goss.
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
Study Summary
Sputum culture has been the best approach to detect harmful bacteria in the lungs of people with cystic fibrosis (CF). With the widespread use of new CF therapies (like Trikafta and Alyftrak), it is more difficult for people with CF to produce sputum even though they still have harmful bacteria in their lungs. The SEND-CF study is being done to see if there are other ways to detect harmful bacteria in the lungs.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2026-03-30 |
| Est. Completion | 2027-08-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07312734
The ClinicalTrials.gov registry entry for NCT07312734 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Chris Goss, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT07312734 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07312734 about?
NCT07312734 is a clinical study titled "Study to Enable New Diagnostics for Pulmonary Microbes in People With CF". Sputum culture has been the best approach to detect harmful bacteria in the lungs of people with cystic fibrosis (CF). With the widespread use of new CF therapies (like Trikafta and Alyftrak), it is more difficult for people with CF to produce sputum even though they still have harmful bacteria in t...
What is the current status of trial NCT07312734?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2026-03-30. Estimated completion is 2027-08-01.
Who is sponsoring clinical trial NCT07312734?
This trial is sponsored by Chris Goss, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.